 <h1>Oseltamivir Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of oseltamivir include:</b> nausea and vomiting. <b>Other side effects include:</b> abdominal pain.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to oseltamivir: oral capsule, oral powder for suspension</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, oseltamivir may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking oseltamivir:</p><p>
<i>Less common</i>
</p><ul>
<li>Phlegm-producing cough</li>
<li>wheezing</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Abdominal or stomach cramps or tenderness</li>
<li>arm, back, or jaw pain</li>
<li>bloating</li>
<li>chest pain or discomfort</li>
<li>diarrhea, watery and severe, which may also be bloody</li>
<li>drooling</li>
<li>facial swelling</li>
<li>fast or irregular heartbeat</li>
<li>hoarseness</li>
<li>increased thirst</li>
<li>pain</li>
<li>shortness of breath</li>
<li>unusual weight loss</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>convulsions (seizures)</li>
<li>dark urine</li>
<li>difficulty with swallowing</li>
<li>fainting</li>
<li>fast, slow, or irregular heartbeat</li>
<li>hives or welts</li>
<li>itching, puffiness, or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>joint or muscle pain</li>
<li>light-colored stools</li>
<li>loss of bladder control</li>
<li>loss of consciousness</li>
<li>muscle spasm or jerking of all extremities</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>skin rash or itching over the entire body</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>sweating</li>
<li>upper right abdominal or stomach pain</li>
<li>yellow eyes and skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of oseltamivir may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
<li>nausea</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>bloody nose or unexplained nosebleeds (occurs mainly in children)</li>
<li>burning, dry, or itching eyes (mainly in children)</li>
<li>dizziness</li>
<li>ear disorder (occurs mainly in children)</li>
<li>excessive tearing of the eyes (mainly in children)</li>
<li>redness, pain, or swelling of the eye or eyelid (mainly in children)</li>
<li>trouble with sleeping</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Pale skin</li>
<li>troubled breathing</li>
<li>unusual bleeding or bruising</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>blurred vision</li>
<li>cracked, dry, or scaly skin</li>
<li>dry mouth</li>
<li>flushed, dry skin</li>
<li>mood or mental changes</li>
<li>skin rash that is encrusted, scaly, and oozing</li>
</ul><p>
<!-- end oral capsule, oral powder for suspension --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to oseltamivir: oral capsule, oral powder for reconstitution</i></p><h3>General</h3><p>The most common side effects were nausea and vomiting.</p>
<p></p>
<p>The most common side effects reported with this drug during studies for the treatment of influenza were nausea, vomiting, and headache; the most common side effects reported in prophylaxis studies were nausea, vomiting, headache, and pain.  Most side effects were reported on a single occasion, occurred on the first or second day of therapy, and resolved spontaneously within 1 to 2 days.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 17%)</p>
<p><b>Common</b> (1% to 10%): Dizziness, vertigo</p>
<p><b>Frequency not reported</b>: Drowsiness</p>
<p><b>Postmarketing reports</b>: Seizure/convulsion<sup>[Ref]</sup></p><p>Side effects with similar or higher incidence among placebo patients included dizziness and vertigo.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea</p>
<p><b>Common</b> (1% to 10%): Vomiting, diarrhea, abdominal pain, upper abdominal pain, dyspepsia</p>
<p><b>Frequency not reported</b>: Pseudomembranous colitis</p>
<p><b>Postmarketing reports</b>: Gastrointestinal bleeding, hemorrhagic colitis<sup>[Ref]</sup></p><p>Side effects with similar or higher incidence among placebo patients included diarrhea, abdominal pain, upper abdominal pain, and dyspepsia.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Nasal congestion, cough, sore throat, bronchitis, nasopharyngitis, upper respiratory tract infections, influenza, rhinorrhea, sinusitis</p>
<p><b>Frequency not reported</b>: Pneumonia, peritonsillar abscess, congestion, rhinitis, dry sore throat, epistaxis, asthma, aggravated asthma<sup>[Ref]</sup></p><p>Side effects with similar or higher incidence among placebo patients included cough, nasal congestion, sore throat, rhinorrhea, bronchitis, sinusitis, nasopharyngitis, upper respiratory tract infections, and influenza.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia</p>
<p><b>Frequency not reported</b>: Mania</p>
<p><b>Postmarketing reports</b>: Abnormal behavior, delirium, altered level of consciousness, confusion, delusions, hallucinations, agitation, anxiety, nightmares, self-injury<sup>[Ref]</sup></p><p>Influenza can be associated with various neurologic and behavioral symptoms (including hallucinations, delirium, abnormal behavior), with fatal outcomes in some cases; such events may occur with encephalitis or encephalopathy but can occur without obvious severe disease.  There are postmarketing reports (mostly in Japan) of delirium and abnormal behavior leading to injury, with fatal outcomes in some cases, in influenza patients using this drug.  Although frequency is unknown, based on usage, these events appear uncommon.  These events were primarily reported in pediatric patients, often with abrupt onset and rapid resolution.  The contribution of this drug to such events has not been established.</p>
<p></p>
<p>Side effects with similar or higher incidence among placebo patients included insomnia.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue, pain, pyrexia, influenza-like illness, pain in limb, otitis media, earache</p>
<p><b>Uncommon</b> (0.1% to 1%): Tympanic membrane disorder</p>
<p><b>Frequency not reported</b>: Humerus fracture, malaise, sepsis, facial edema, ear disorder, accidental injury</p>
<p><b>Postmarketing reports</b>: Hypothermia<sup>[Ref]</sup></p><p>Side effects with similar or higher incidence among placebo patients included fatigue, pyrexia, influenza-like illness, and pain in limb.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Herpes simplex</p>
<p><b>Uncommon</b> (0.1% to 1%): Dermatitis (including allergic and atopic dermatitis)</p>
<p><b>Rare</b> (less than 0.1%): Angioneurotic edema</p>
<p><b>Postmarketing reports</b>: Rash, urticaria, eczema, serious skin reactions, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme<sup>[Ref]</sup></p><p>Side effects with similar or higher incidence among placebo patients included herpes simplex.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, arthralgia, myalgia<sup>[Ref]</sup></p><p>Side effects with similar or higher incidence among placebo patients included back pain, arthralgia, and myalgia.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Dysmenorrhea</p><p>Side effects with similar or higher incidence among placebo patients included dysmenorrhea.</p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Conjunctivitis (including red eyes, eye discharge, eye pain)</p>
<p><b>Postmarketing reports</b>: Visual disturbances<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Elevated liver enzymes</p>
<p><b>Rare</b> (less than 0.1%): Hepatic failure, fulminant hepatitis (including fatalities)</p>
<p><b>Frequency not reported</b>: Hepatic function disorder, jaundice</p>
<p><b>Postmarketing reports</b>: Hepatitis, abnormal liver function tests<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Hypersensitivity reactions (e.g., allergic skin reactions), allergy, anaphylactic/anaphylactoid reactions, swelling of the face or tongue<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Cardiac arrhythmia</p>
<p><b>Frequency not reported</b>: Unstable angina, sudden cardiopulmonary arrest</p>
<p><b>Postmarketing reports</b>: Arrhythmia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Hyperglycemia</p>
<p><b>Postmarketing reports</b>: Aggravation of diabetes<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Anemia, pancytopenia, lymphadenopathy</p>
<p><b>Postmarketing reports</b>: Thrombocytopenia<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Moscona A "Neuraminidase inhibitors for influenza." N Engl J Med 353 (2005): 1363-73</p><p id="ref_3">3. Montalto NJ, Gum KD, Ashley JV "Updated treatment for influenza A and B." Am Fam Physician 62 (2000): 2467-76</p><p id="ref_4">4. "Antiviral drugs prophylaxis and treatment of influenza." Med Lett Drugs Ther 48 (2006): 87-8</p><p id="ref_5">5. Dreitlein WB, Maratos J, Brocavich J "Zanamivir and oseltamivir: Two new options for the treatment and prevention of influenza." Clin Ther 23 (2001): 327-55</p><p id="ref_6">6. Nicholson KG, Aoki FY, Osterhaus AD, et al. "Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial." Lancet 355 (2000): 1845-50</p><p id="ref_7">7. McNicholl IR,  McNicholl JJ "Neuraminidase inhibitors: zanamivir and oseltamivir." Ann Pharmacother 35 (2001): 57-70</p><p id="ref_8">8. Treanor JJ, Hayden FG, Vrooman PS, et al. "Efficacy and safety of the oral neuramidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial." JAMA 283 (2000): 1016-24</p><p id="ref_9">9. Cox NJ, Hughes JM "New options for the prevention of influenza." N Engl J Med 341 (1999): 1387-8</p><p id="ref_10">10. McClellan K, Perry CM "Oseltamivir: a review of its use in influenza." Drugs 61 (2001): 263-83</p><p id="ref_11">11. Welliver R, Monto AS, Carewicz O, et al. "Effectiveness of oseltamivir in preventing influenza in household contacts." JAMA 285 (2001): 748-54</p><p id="ref_12">12. Snell P,  Dave N,  Wilson K, et al. "Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate." Br J Clin Pharmacol 59 (2005): 598-601</p><p id="ref_13">13. "Product Information. Tamiflu (oseltamivir)" RocheLaboratories, Nutley, NJ. </p><p id="ref_14">14. He G, Massarella J, Ward P "Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802." Clin Pharmacokinet 37 (1999): 471-84</p><p id="ref_15">15. Hayden FG, Atmar RL, Schilling M, et al. "Use of selective oral neura minidase inhibitor oseltamivir to prevent influenza." N Engl J Med 341 (1999): 1336-43</p><p id="ref_16">16. Bardsley-Elliot A, Noble S "Oseltamivir." Drugs 58 (1999): 851-60</p><p id="ref_17">17. Jefferson T,  Demicheli V,  Rivetti D,  Jones M,  Di Pietrantonj C,  Rivetti A "Antivirals for influenza in healthy adults: systematic review." Lancet 367 (2006): 303-13</p><p id="ref_18">18. "Antiviral drugs for influenza 2012-2013." Med Lett Drugs Ther 54 (2012): 97-8</p><p id="ref_19">19. "New concerns about oseltamivir." Lancet 369 (2007): 1056</p><p id="ref_20">20. "Antiviral drugs for influenza." Med Lett Drugs Ther 54 (2012): 1-3</p><p id="ref_21">21. Strong M,  Burrows J,  Redgrave P "A/H1N1 pandemic. Oseltamivir's adverse events." BMJ 339 (2009): b3249</p><p id="ref_22">22. Anekthananon T,  Pukritayakamee S,  Ratanasuwan W, et al. "Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks." J Antimicrob Chemother 68 (2013): 697-707</p><p id="ref_23">23. Jefferson T,  Jones M,  Doshi P,  Del Mar C "Possible harms of oseltamivir-a call for urgent action." Lancet 374 (2009): 1312-3</p><p id="ref_24">24. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_25">25. Hama R "Oseltamivir's adverse reactions: Fifty sudden deaths may be related to central suppression." BMJ 335 (2007): 59</p><p id="ref_26">26. Ho LN,  Chung JP,  Choy KL "Oseltamivir-induced mania in a patient with H1N1." Am J Psychiatry 167 (2010): 350</p><p id="ref_27">27. Abe M,  Smith J,  Urae A,  Barrett J,  Kinoshita H,  Rayner CR "Pharmacokinetics of Oseltamivir in Young and Very Elderly Subjects (October)." Ann Pharmacother  (2006):</p><p id="ref_28">28. Hankey GJ "Clopidogrel and thrombotic thrombocytopenic purpura." Lancet 356 (2000): 269-70</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Does Tamiflu (oseltamivir) work on COVID-19?</li>
<li>What is the difference between Xofluza and Tamiflu?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about oseltamivir</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>575 Reviews</li>
<li>Drug class: neuraminidase inhibitors</li>
<li>FDA Alerts (1)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Oseltamivir &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Tamiflu</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +4 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Avian Influenza</li>
<li>Influenza Prophylaxis</li>
<li>Influenza</li>
<li>Swine Flu</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to oseltamivir: oral capsule, oral powder for reconstitution</i></p><h3>General</h3><p>The most common side effects were nausea and vomiting.</p><p></p><p>The most common side effects reported with this drug during studies for the treatment of influenza were nausea, vomiting, and headache; the most common side effects reported in prophylaxis studies were nausea, vomiting, headache, and pain.  Most side effects were reported on a single occasion, occurred on the first or second day of therapy, and resolved spontaneously within 1 to 2 days.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 17%)</p><p><b>Common</b> (1% to 10%): Dizziness, vertigo</p><p><b>Frequency not reported</b>: Drowsiness</p><p><b>Postmarketing reports</b>: Seizure/convulsion<sup>[Ref]</sup></p><p>Side effects with similar or higher incidence among placebo patients included dizziness and vertigo.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea</p><p><b>Common</b> (1% to 10%): Vomiting, diarrhea, abdominal pain, upper abdominal pain, dyspepsia</p><p><b>Frequency not reported</b>: Pseudomembranous colitis</p><p><b>Postmarketing reports</b>: Gastrointestinal bleeding, hemorrhagic colitis<sup>[Ref]</sup></p><p>Side effects with similar or higher incidence among placebo patients included diarrhea, abdominal pain, upper abdominal pain, and dyspepsia.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Nasal congestion, cough, sore throat, bronchitis, nasopharyngitis, upper respiratory tract infections, influenza, rhinorrhea, sinusitis</p><p><b>Frequency not reported</b>: Pneumonia, peritonsillar abscess, congestion, rhinitis, dry sore throat, epistaxis, asthma, aggravated asthma<sup>[Ref]</sup></p><p>Side effects with similar or higher incidence among placebo patients included cough, nasal congestion, sore throat, rhinorrhea, bronchitis, sinusitis, nasopharyngitis, upper respiratory tract infections, and influenza.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia</p><p><b>Frequency not reported</b>: Mania</p><p><b>Postmarketing reports</b>: Abnormal behavior, delirium, altered level of consciousness, confusion, delusions, hallucinations, agitation, anxiety, nightmares, self-injury<sup>[Ref]</sup></p><p>Influenza can be associated with various neurologic and behavioral symptoms (including hallucinations, delirium, abnormal behavior), with fatal outcomes in some cases; such events may occur with encephalitis or encephalopathy but can occur without obvious severe disease.  There are postmarketing reports (mostly in Japan) of delirium and abnormal behavior leading to injury, with fatal outcomes in some cases, in influenza patients using this drug.  Although frequency is unknown, based on usage, these events appear uncommon.  These events were primarily reported in pediatric patients, often with abrupt onset and rapid resolution.  The contribution of this drug to such events has not been established.</p><p></p><p>Side effects with similar or higher incidence among placebo patients included insomnia.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue, pain, pyrexia, influenza-like illness, pain in limb, otitis media, earache</p><p><b>Uncommon</b> (0.1% to 1%): Tympanic membrane disorder</p><p><b>Frequency not reported</b>: Humerus fracture, malaise, sepsis, facial edema, ear disorder, accidental injury</p><p><b>Postmarketing reports</b>: Hypothermia<sup>[Ref]</sup></p><p>Side effects with similar or higher incidence among placebo patients included fatigue, pyrexia, influenza-like illness, and pain in limb.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Herpes simplex</p><p><b>Uncommon</b> (0.1% to 1%): Dermatitis (including allergic and atopic dermatitis)</p><p><b>Rare</b> (less than 0.1%): Angioneurotic edema</p><p><b>Postmarketing reports</b>: Rash, urticaria, eczema, serious skin reactions, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme<sup>[Ref]</sup></p><p>Side effects with similar or higher incidence among placebo patients included herpes simplex.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, arthralgia, myalgia<sup>[Ref]</sup></p><p>Side effects with similar or higher incidence among placebo patients included back pain, arthralgia, and myalgia.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Dysmenorrhea</p><p>Side effects with similar or higher incidence among placebo patients included dysmenorrhea.</p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Conjunctivitis (including red eyes, eye discharge, eye pain)</p><p><b>Postmarketing reports</b>: Visual disturbances<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Elevated liver enzymes</p><p><b>Rare</b> (less than 0.1%): Hepatic failure, fulminant hepatitis (including fatalities)</p><p><b>Frequency not reported</b>: Hepatic function disorder, jaundice</p><p><b>Postmarketing reports</b>: Hepatitis, abnormal liver function tests<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Hypersensitivity reactions (e.g., allergic skin reactions), allergy, anaphylactic/anaphylactoid reactions, swelling of the face or tongue<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Cardiac arrhythmia</p><p><b>Frequency not reported</b>: Unstable angina, sudden cardiopulmonary arrest</p><p><b>Postmarketing reports</b>: Arrhythmia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Hyperglycemia</p><p><b>Postmarketing reports</b>: Aggravation of diabetes<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Anemia, pancytopenia, lymphadenopathy</p><p><b>Postmarketing reports</b>: Thrombocytopenia<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Moscona A "Neuraminidase inhibitors for influenza." N Engl J Med 353 (2005): 1363-73</p><p id="ref_3">3. Montalto NJ, Gum KD, Ashley JV "Updated treatment for influenza A and B." Am Fam Physician 62 (2000): 2467-76</p><p id="ref_4">4. "Antiviral drugs prophylaxis and treatment of influenza." Med Lett Drugs Ther 48 (2006): 87-8</p><p id="ref_5">5. Dreitlein WB, Maratos J, Brocavich J "Zanamivir and oseltamivir: Two new options for the treatment and prevention of influenza." Clin Ther 23 (2001): 327-55</p><p id="ref_6">6. Nicholson KG, Aoki FY, Osterhaus AD, et al. "Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial." Lancet 355 (2000): 1845-50</p><p id="ref_7">7. McNicholl IR,  McNicholl JJ "Neuraminidase inhibitors: zanamivir and oseltamivir." Ann Pharmacother 35 (2001): 57-70</p><p id="ref_8">8. Treanor JJ, Hayden FG, Vrooman PS, et al. "Efficacy and safety of the oral neuramidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial." JAMA 283 (2000): 1016-24</p><p id="ref_9">9. Cox NJ, Hughes JM "New options for the prevention of influenza." N Engl J Med 341 (1999): 1387-8</p><p id="ref_10">10. McClellan K, Perry CM "Oseltamivir: a review of its use in influenza." Drugs 61 (2001): 263-83</p><p id="ref_11">11. Welliver R, Monto AS, Carewicz O, et al. "Effectiveness of oseltamivir in preventing influenza in household contacts." JAMA 285 (2001): 748-54</p><p id="ref_12">12. Snell P,  Dave N,  Wilson K, et al. "Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate." Br J Clin Pharmacol 59 (2005): 598-601</p><p id="ref_13">13. "Product Information. Tamiflu (oseltamivir)" RocheLaboratories, Nutley, NJ. </p><p id="ref_14">14. He G, Massarella J, Ward P "Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802." Clin Pharmacokinet 37 (1999): 471-84</p><p id="ref_15">15. Hayden FG, Atmar RL, Schilling M, et al. "Use of selective oral neura minidase inhibitor oseltamivir to prevent influenza." N Engl J Med 341 (1999): 1336-43</p><p id="ref_16">16. Bardsley-Elliot A, Noble S "Oseltamivir." Drugs 58 (1999): 851-60</p><p id="ref_17">17. Jefferson T,  Demicheli V,  Rivetti D,  Jones M,  Di Pietrantonj C,  Rivetti A "Antivirals for influenza in healthy adults: systematic review." Lancet 367 (2006): 303-13</p><p id="ref_18">18. "Antiviral drugs for influenza 2012-2013." Med Lett Drugs Ther 54 (2012): 97-8</p><p id="ref_19">19. "New concerns about oseltamivir." Lancet 369 (2007): 1056</p><p id="ref_20">20. "Antiviral drugs for influenza." Med Lett Drugs Ther 54 (2012): 1-3</p><p id="ref_21">21. Strong M,  Burrows J,  Redgrave P "A/H1N1 pandemic. Oseltamivir's adverse events." BMJ 339 (2009): b3249</p><p id="ref_22">22. Anekthananon T,  Pukritayakamee S,  Ratanasuwan W, et al. "Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks." J Antimicrob Chemother 68 (2013): 697-707</p><p id="ref_23">23. Jefferson T,  Jones M,  Doshi P,  Del Mar C "Possible harms of oseltamivir-a call for urgent action." Lancet 374 (2009): 1312-3</p><p id="ref_24">24. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_25">25. Hama R "Oseltamivir's adverse reactions: Fifty sudden deaths may be related to central suppression." BMJ 335 (2007): 59</p><p id="ref_26">26. Ho LN,  Chung JP,  Choy KL "Oseltamivir-induced mania in a patient with H1N1." Am J Psychiatry 167 (2010): 350</p><p id="ref_27">27. Abe M,  Smith J,  Urae A,  Barrett J,  Kinoshita H,  Rayner CR "Pharmacokinetics of Oseltamivir in Young and Very Elderly Subjects (October)." Ann Pharmacother  (2006):</p><p id="ref_28">28. Hankey GJ "Clopidogrel and thrombotic thrombocytopenic purpura." Lancet 356 (2000): 269-70</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Does Tamiflu (oseltamivir) work on COVID-19?</li>
<li>What is the difference between Xofluza and Tamiflu?</li>
</ul><h2>More about oseltamivir</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>575 Reviews</li>
<li>Drug class: neuraminidase inhibitors</li>
<li>FDA Alerts (1)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Oseltamivir &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +4 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Avian Influenza</li>
<li>Influenza Prophylaxis</li>
<li>Influenza</li>
<li>Swine Flu</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>